title: Antibacterial activity of mometasone furoate.
abstract: OBJECTIVE
  To test the antibacterial properties of the topical corticoid mometasone furoate, which is used as a nasal spray.
  
  
  METHODS
  The activity of mometasone (0.01%, 0.1%, and 0.5%) in buffer solution against Staphylococcus aureus, Pseudomonas aeruginosa, Escherichia coli, Streptococcus pyogenes, and Streptococcus milleri was tested by quantitative killing assays.
  
  
  METHODS
  In vitro study.
  
  
  METHODS
  Reduction of viable bacteria and fungi in quantitative killing assays.
  
  
  RESULTS
  Mometasone (0.5%) reduced viable counts of S pyogenes and S milleri by 99.99% and 99.00%, respectively, after 24 hours of incubation, whereas colony-forming units (CFUs) of S aureus, P aeruginosa, and E coli were not affected by the corticoid. Mometasone (0.1%) caused a decrease in CFUs of S pyogenes of 99.90% to 99.99%, while it led to a 99.00% reduction in CFUs of S milleri, but only if low bacterial counts of 1 x 10(4) CFUs/mL were incubated. By contrast, the use of mometasone at a low concentration (0.01%) demonstrated an increase in CFUs of S milleri if the baseline bacterial count was low (1 x 10(4) CFUs/mL).
  
  
  CONCLUSIONS
  Mometasone demonstrates antimicrobial activity against streptococci.
authors.affiliation: Department of Otorhinolaryngology, Innsbruck Medical University, Anichstr 35, Innsbruck, Austria. Andreas.Neher@i-med.ac.at
authors.forename: Andreas
authors.initials: A
authors.lastname: Neher
authors.forename: Michaela
authors.initials: M
authors.lastname: Gstöttner
authors.forename: Arne
authors.initials: A
authors.lastname: Scholtz
authors.forename: Markus
authors.initials: M
authors.lastname: Nagl
mesh_terms: D000281:Administration, Intranasal; D000336:Aerosols; D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D000893:Anti-Inflammatory Agents / Q000494:pharmacology*; D002478:Cells, Cultured; D004926:Escherichia coli / Q000187:drug effects*; D006095:Gram-Positive Cocci / Q000187:drug effects*; D006801:Humans; D008826:Microbial Sensitivity Tests; D050296:Microbial Viability / Q000187:drug effects; D000068656:Mometasone Furoate; D010038:Otorhinolaryngologic Diseases / Q000188:drug therapy* / Q000382:microbiology; D011244:Pregnadienediols / Q000494:pharmacology*; D011550:Pseudomonas aeruginosa / Q000187:drug effects*; D013211:Staphylococcus aureus / Q000187:drug effects; D034364:Streptococcus milleri Group / Q000187:drug effects; D013297:Streptococcus pyogenes / Q000187:drug effects
chemical_list: D000336:Aerosols; D000900:Anti-Bacterial Agents; D000893:Anti-Inflammatory Agents; D011244:Pregnadienediols; D000068656:Mometasone Furoate